V1RC27 Inhibitors
V1RC27 inhibitors represent a specialized category of chemical compounds characterized by their ability to selectively bind to and inhibit the function of a specific biological target known as V1RC27. This target is typically a protein or enzyme that plays a pivotal role in a particular biochemical pathway. The structure of V1RC27 inhibitors is often complex, involving multiple functional groups that confer the ability to engage with the active site or a regulatory region of the V1RC27 protein. The design of these molecules is informed by an intricate understanding of the molecular architecture of V1RC27, which allows these inhibitors to achieve a high degree of specificity. By fitting snugly into the target site, these inhibitors can effectively block the normal activity of V1RC27, leading to a modulation of the biochemical pathway in which the protein is involved.
The development and refinement of V1RC27 inhibitors hinge on advanced techniques in medicinal chemistry and molecular biology. Researchers employ methods such as structure-activity relationship (SAR) studies to ascertain how different chemical modifications affect the binding affinity and selectivity of the inhibitors. This is often a meticulous process, requiring iterative cycles of synthesis and testing to hone the properties of the inhibitor compounds. High-resolution structural determination methods, like X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy, are commonly used to visualize the interaction between V1RC27 inhibitors and their target. Additionally, computational tools, including molecular docking and dynamics simulations, play a significant role in predicting how potential inhibitors might interact with V1RC27. These computational models help streamline the discovery process by identifying promising candidates for synthesis and further experimental evaluation. Overall, the design of V1RC27 inhibitors is a sophisticated endeavor that leverages cutting-edge science to precisely modulate the function of the targeted protein.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is a specific inhibitor of the Akt signaling pathway. As V1RC27 is activated by PI3K/Akt signaling, triciribine would lead to the inhibition of V1RC27 by preventing the activation of Akt, and consequently reducing the phosphorylation and activation of downstream proteins including V1RC27. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, LY294002 prevents the formation of PIP3 and the subsequent activation of Akt. This results in decreased activation of downstream effectors, such as V1RC27, that rely on PI3K/Akt signaling for their activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2 which blocks the MAPK/ERK pathway. Although V1RC27 may not be a direct target of this pathway, its functional activity can be indirectly affected if it is downstream or reliant on MAPK/ERK signaling for activation or stabilization. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an inhibitor of the mTOR (mammalian target of rapamycin) pathway. By inhibiting mTOR complex 1 (mTORC1), rapamycin reduces protein synthesis and cellular proliferation, which could result in a decrease in V1RC27 protein levels if its expression is mTOR-dependent. | ||||||
WZ8040 | 1214265-57-2 | sc-364656 sc-364656A | 5 mg 10 mg | $255.00 $480.00 | ||
WZ4003 is a selective inhibitor of NUAK family kinase 1 (NUAK1), which is involved in cellular stress responses. By inhibiting NUAK1, WZ4003 could disrupt stress signaling pathways that may regulate the stability or localization of V1RC27, leading to its inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). As JNK is involved in stress and inflammatory responses, inhibiting JNK with SP600125 could lead to the indirect inhibition of V1RC27 if it plays a role in these JNK-mediated signaling processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. By blocking p38 MAPK signaling, SB203580 could prevent the activation of transcription factors or other proteins that are required for V1RC27 expression or function, leading to its inhibition. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
XAV-939 is a tankyrase inhibitor which stabilizes axin by preventing its poly(ADP-ribosyl)ation and degradation. Since axin is a component of the β-catenin destruction complex, stabilizing axin with XAV-939 could limit Wnt/β-catenin signaling that may be involved in the regulation of V1RC27. | ||||||
Stat3 Inhibitor VI, S3I-201 | 501919-59-1 | sc-204304 | 10 mg | $151.00 | 104 | |
S3I-201 is an inhibitor of the STAT3 activation pathway. By preventing STAT3 phosphorylation and dimerization, S3I-201 could inhibit transcriptional events that lead to the expression of V1RC27, assuming V1RC27 is a STAT3-regulated gene. | ||||||
GSK 690693 | 937174-76-0 | sc-363280 sc-363280A | 10 mg 50 mg | $255.00 $1071.00 | 4 | |
GSK690693 is an inhibitor of Akt kinase activity. By inhibiting Akt, GSK690693 would reduce the phosphorylation of downstream targets, which could include V1RC27 or proteins that modulate V1RC27 activity, resulting in its functional inhibition. | ||||||